The Variability of HR+ Breast Cancer
Sunil Verma, MD, MSEd, FRCPC
Video Categories: ESMO 2016
Sunil Verma, MD, MSEd, FRCPC discusses treatment options for this type of cancer.
Dr. Ajai Chari talks about risk-based treatment for myeloma as the beginning of personalized medicine in the field. The 2 most recent advances are the increased use of proteasome inhibitors for those with the 4;14 translocation and treating those identified with high molecular risk more aggressively.
Dr. Sanjiv Agarwala analyzes anti-PD-1 and anti-PD-L1 therapies in terms what they do and their unique toxicities and response patterns.